Bluebird’s Gene Therapy Costs $3 Million per Treatment
- On September 16, 2022, the FDA granted bluebird bio accelerated approval for their gene therapy technology, Skysona. This technology is meant to treat active cerebral adrenoleukodystrophy (CALD) in males between 4 and 17 years old. This new therapeutic intervention costs approximately $3 million per treatment, making it more expensive...
